1. To review latest mechanisms and signaling aberrations associated with cavernous angiomas pathogenesis.
2. To present the concept of cavernous angiomas with symptomatic hemorrhage (CASH) and its biomarkers and therapeutic targets.
3. To analyze common genes, biomarkers and potential therapies of cavernous angioma and their application for the aging Neurovascular Unit.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation